---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-030826"
form_type: "8-K"
ticker: "GUTS"
cik: "0001572616"
company_name: "FRACTYL HEALTH, INC."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:43:29.622939+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fractyl Health reports Q4 2024 net loss $25.0M; REMAIN-1 enrollment surges to 189+ patients

## Summary
- Q4 2024 net loss $25.0M vs $19.2M in Q4 2023; R&D expense rose to $20.3M from $10.1M.
- Cash and equivalents $67.5M; cash runway extended into 2026 after pausing T2D Revita programs.
- REMAIN-1 pivotal study enrolled >189 patients across 13 sites; midpoint data expected Q2 2025, full enrollment summer 2025.
- Rejuva RJVA-001 CTA for T2D submission expected H1 2025; preliminary data (if authorized) in 2026.
- Strategic shift: focus Revita on weight maintenance, pause T2D Revita programs (REVITALIZE-1, Germany Registry).

## SEC filing metadata
- accession: 0000950170-25-030826
- form_type: 8-K
- ticker: GUTS
- cik: 0001572616
- company_name: FRACTYL HEALTH, INC.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1572616/000095017025030826/0000950170-25-030826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1572616/000095017025030826/guts-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-030826
- JSON: https://secwatch.observer/filing/0000950170-25-030826.json
- Plain text: https://secwatch.observer/filing/0000950170-25-030826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.